FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine, namely to an antitumor irinotecan liposomal composition containing irinotecan sucrose-octasulfate encapsulated in lipid vesicles containing one or more phospholipids, wherein the liposomal composition contains the total amount in the range from 150 to 550 mg of irinotecan base per mmol of total phospholipids, as well as relates to an antitumor irinotecan liposomal composition containing liposomes, in which irinotecan is encapsulated in the form of salt selected from pyrophosphate, triphosphate and inositohexaphosphate, wherein the specified composition contains lecithin, cholesterol and amphipathic polymer, and the specified composition has from about 0.15 to about 1.5 mol of irinotecan per mol of total lipid, also relates to an antitumor irinotecan liposomal composition containing lipid vesicles in the form of liposomal dispersion, where irinotecan and sucrose-octasulfate are encapsulated in lipid vesicles so that irinotecan and sucrose-octasulfate form gel or precipitation in the form of salt, wherein the specified composition contains lecithin, cholesterol and amphipathic polymer, and the specified composition has from about 0.15 to about 1.5 mol of irinotecan per mol of total lipid, also relates to an antitumor irinotecan liposomal composition containing liposome in aqueous medium, wherein liposome contains 1,2-distearoyl-SN-phosphatidylcholine, cholesterol and N-(omega-methoxypoly(ethylene glycol)oxycarbonyl)-1,2-distearoyl phosphatidylethanolamine in the molar ratio of 3:2:0.015, and irinotecan and sucrose-octasulfate are captured inside liposome.
EFFECT: group of inventions provides for the creation of liposomal compositions that not only have exceptional capability of substance encapsulation, but also provide for improved stability of the specified encapsulated substance, for example, drug, and prevent its untimely release from liposome in a living organism.
22 cl, 47 dwg, 40 tbl, 74 ex
Title | Year | Author | Number |
---|---|---|---|
LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
LIPOSOME HAVING INNER AQUEOUS PHASE AND CONTAINING SULPHOBUTYL ESTER CYCLODEXTRIN SALT | 2010 |
|
RU2575793C2 |
LIPOSOMAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2734900C1 |
STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR PREPARING IT | 2007 |
|
RU2494729C2 |
GRANZYME B DELIVERY METHOD TO MAMMALIAN CELLS | 2021 |
|
RU2796685C2 |
APPLICATION OF MITOXANTHONE HYDROCHLORIDE LIPOSOM FOR THE TREATMENT OF BREAST CANCER | 2021 |
|
RU2806277C1 |
CREATING CONTROLLED RELEASE PROFILE OF DRUG SUBSTANCE USING LIPOSOMAL COMPOSITION IN AQUEOUS AND ANHYDROUS SOLUTIONS | 2014 |
|
RU2712157C2 |
ANTITUMORAL AGENT ON BASIS OF IMMUNOPOLISOME BIOLOGICAL STRUCTURE, WAY OF ITS OBTAINING AND VECTORIAL DELIVERY IN CENTRAL NERVOUS SYSTEM AT TUMORAL PROCESS | 2007 |
|
RU2336901C1 |
NEW LIPOSOME COMPOSITIONS | 2006 |
|
RU2454229C2 |
Authors
Dates
2021-10-11—Published
2015-12-23—Filed